| Date | Title | Description |
| 27.05.2026 | Announcement of The Shaw Laureates 2026 | HONG KONG, May 27, 2026 /PRNewswire/ --
The Shaw Prize in Astronomy is awarded in equal shares to
Ken'ichi Nomoto
Emeritus Professor and Visiting Senior Scientist of the Kavli Institute for the Physics and Mathematics of the Universe, Unive... |
| 18.05.2026 | Hantavirus-stricken cruise ship docks in the Netherlands for disinfection | Getting your Trinity Audio player ready...
By MOLLY QUELL
ROTTERDAM, Netherlands (AP) — The cruise ship hit by a deadly hantavirus outbreak has docked at the Dutch port of Rotterdam for disinfection, wrapping up a troubled journey that put ... |
| 14.05.2026 | Tests in Italy, Spain come back negative in global hunt for hantavirus | ROME: Seventeen people under observation in Italy and Spain for possible hantavirus infection have tested negative, the countries' health ministries said on Wednesday (May 13) as governments around the globe track the virus to stop it from ... |
| 24.04.2026 | Kurma Partners: €215 Million Biofund IV Closes As Total AUM Reach €1 Billion | Kurma Partners, a Paris-based European healthcare venture capital firm and Eurazeo group company, has announced the final closing of Biofund IV at €215 million, bringing total assets under management across all Kurma Partners franchises to ... |
| 14.03.2026 | Elaia Fuels Europe's Deep Tech Future with €134M Fund | Elaia has closed its €134 million DTS3 fund. This deep tech seed fund targets European B2B startups. It doubles prior deep tech allocations. Elaia partners with top research institutions. The fund invests €1M-€13M in early-stage ventures. F... |
| 12.03.2026 | Elaia closes third DeepTech Seed fund at €134 million as “European DeepTech is reaching escape velocity” | Paris-based VC firm Elaia has announced the closing of its third DeepTech Seed fund (DTS3) at €134 million, which is double the size of its previous DeepTech Seed funds.
DTS3’s final closing includes support from longtime partners and new i... |
| 20.02.2026 | Учёные обнаружили древнего любителя кислорода — предка всех сложных форм жизни | Учёные обычно согласны с тем, что сложные формы жизни появились после того, как два очень разных микроорганизма образовали тесное партнёрство. Это слияние в конечном итоге привело к появлению растений, животных и грибов, известных под общим... |
| 11.01.2026 | Enodia Therapeutics Secures €20.7M Seed Funding to Pioneer Protein Degradation with AI | Enodia Therapeutics, a pioneering biotech firm, secured a significant €20.7 million ($25 million) seed funding round. This vital capital propels its innovative small-molecule platform, a breakthrough approach targeting protein degradation a... |
| 11.01.2026 | Enodia Therapeutics Raises €20.7M to Target "Undruggable" Proteins with SEC61 Platform | Enodia Therapeutics, a Paris-based biotech, has secured €20.7 million ($25 million) in seed funding. Argobio Studio launched the company. Enodia develops small molecules. Its platform targets protein degradation at the point of synthesis. I... |
| 10.01.2026 | Enodia Therapeutics: €20.7 Million Seed Funding Closed To Advance SEC61-Based Small-Molecule Protein Degradation Platform | Enodia Therapeutics has raised €20.7 million (about $25 million) in a seed financing to advance a discovery platform that uses proteomics and machine learning to develop small molecules that degrade disease-driving proteins at the point of ... |
| 09.01.2026 | Argobio Launches Enodia With €20.7 Million Seed Round To Develop Small Molecules For Protein Degradation | Argobio Studio announced it has launched Enodia Therapeutics and completed a €20.7 million ($25 million) seed financing to advance a small-molecule platform for targeted protein degradation at the point of protein synthesis, enabled by prot... |
| 08.01.2026 | Enodia Therapeutics Raises €20.7M in Seed Funding | Enodia Therapeutics, a Paris, France-based biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, raised €20.7m (US$25m) in Seed financing.
The round was co-led by Elaia, ... |
| 18.06.2025 | Biocellis and General Inception announce equity partnership and strategic collaboration with Institut Pasteur. | Biocellis, an emerging player in biological research and in vitro diagnostic, announces equity partnership with General Inception and strategic collaboration with Institut Pasteur. This alliance will accelerate Biocellis' development and co... |
| 29.05.2025 | Kyron.bio: Pioneering a New Era in Antibody Therapeutics | In the bustling world of biotechnology, a new player is making waves. Kyron.bio, a Paris-based startup, has secured €5.5 million in seed funding to revolutionize drug development. This funding is not just a financial boost; it’s a lifeline ... |
| 28.05.2025 | Paris-based kyron.bio secures €5.5 million to tackle drug efficiency and safety | French BioTech company kyron.bio announced today a €5.5 million Seed funding round to tackle the issues of varying efficacy and dangerous side effects in current drug development, using control of sugar molecules – also known as glycans.
Th... |
| 22.04.2025 | Advanced Biological Laboratories (ABL) S.A Inks Licensing Agreement with the Institut Pasteur for HPV RNA-Seq Technology | HPV Transcriptome as a Game-Changing Biomarker for Detection, Genotyping, and Monitoring of HPV-Associated Cervical High-Grade Cytology LUXEMBOURG, LUXEMBOURG, April 22, 2025 /EINPresswire.com/ -- Advanced Biological Laboratories (ABL), a d... |
| 20.02.2025 | Spore.Bio secures $23M Series A for on-site microbiology testing | Microbiology testing startup Spore.Bio has raised $23 million Series A, bringing its total funding to date to $31.3 million.
Recent years have seen a sharp rise in product recalls and contamination incidents across the FMCG industry.
These ... |
| 20.02.2025 | Spore.Bio raises €22 million to deploy a new generation of AI-based microbiology testing | Paris-based Spore.Bio, a DeepTech startup that developed a proprietary AI technology in microbiology testing, announced today it has secured a €22 million Series A funding round to transform quality control in manufacturing
The oversubscrib... |
| 20.02.2025 | Spore.Bio raises $23M to cut microbiology testing to minutes from days using AI
Your vote of support is important to us and it helps us keep the content FREE.
One click below supports our mission to p... | Paris-based Spore.Bio, a startup that developed an artificial intelligence-driven method for detecting pathogens, said today it has raised $23 million in early-stage funding to reinvent microbiology testing.
The company’s Series A funding r... |
| 04.10.2024 | Human Papillomavirus (HPV)-induced Cancers: First Patient Enrolled in Phase I/IIa Clinical Trial for Lenti-HPV-07, the TheraVectys’ Therapeutic Vaccine Candidate Against Oropharyngeal and Cervical Can... | PARIS–(BUSINESS WIRE)–October 4, 2024–
TheraVectys, a biotechnology company that designs and develops lentiviral vector-based vaccines and immunotherapies against infectious agents and cancers, announces that the first patient has been enro... |
| 05.06.2024 | Illumina launches latest chemistry across most popular mid-throughput sequencers, enabling higher quality and greater speed for customers at lower cost | SAN DIEGO - PRNewswire -- Illumina Inc., a global leader in DNA sequencing and array-based technologies, announces it has completed integration of its latest chemistry, XLEAP-SBS™, into all reagents for its NextSeq™ 1000 and NextSeq 2000 ne... |
| 07.05.2024 | BioVersys and GSK Join Forces to Fight Tuberculosis | BioVersys and GSK team up to tackle tuberculosis with innovative drug development, securing additional funding to push the boundaries of treatment options for patients in need.
In a world where tuberculosis continues to pose a serious threa... |
| 07.05.2024 | BioVersys strengthens tuberculosis drug development with expanded GSK collaboration and CHF 12.3 million Series C boost | "Venture Kick was really kicking BioVersys out of the comfort zone
and into full start mode. Funny anecdote: During one of the kickers camps was
my first outreach to our now long-term partner GSK...
...talking impact of Venture Kick!&q... |
| 25.07.2023 | Lady Mireille and Sir Dennis Gillings Global Public Health Fellowships advance the next generation of leaders | NEW YORK, and PARIS, July 25, 2023 /PRNewswire/ -- The Pasteur Foundation US and the Institut Pasteur are pleased to announce that the 2023 cohort of Lady Mireille and Sir Dennis Gillings Global Public Health Fellowships have been conferred... |
| 26.11.2021 | “World’s first” 3D printed immunized skin model enables cold plasma wound healing treatment for burns | The NOVOPLASM consortium has announced it is the “first in the world” to develop cold plasma technology for the treatment of infected burns and the wound healing of skin grafts.
Regenerative medicine firm CTIBIOTECH, the French Armed Forces... |
| 18.11.2021 | Africa’s first mRNA vaccine technology transfer hub gets to work | Employees at the Afrigen biotechnology company and Vaccine Hub facility at work in the manufacturing laboratory. Rodger Bosch/AFP via Getty Images
The World Health Organisation and the COVID Vaccines Global Access (COVAX) initiative announc... |
| 18.11.2021 | Africa’s first mRNA vaccine technology transfer hub gets to work | Employees at the Afrigen biotechnology company and Vaccine Hub facility at work in the manufacturing laboratory. Rodger Bosch/AFP via Getty Images |
| 02.03.2021 | EIT Health welcomes new Partners in live event | EIT Health welcomed 14 new Associate Partners in a 25 February 2021 online event that allowed the newcomers to introduce themselves to our community. Coming from eight different countries, these new Partners enrich EIT Health’s network with... |
| 28.07.2020 | Science points to in-person learning as safe amid COVID-19 pandemic — but is it safe enough for Colorado’s school districts? | As school districts across Colorado grapple with how to re-open amid an ongoing global pandemic, the state’s largest teachers union insists that any decision to return to in-person learning needs to be driven by “scientific standards” and n... |
| 16.04.2020 | Covid-19 vaccine tracker updated to include GSK/Sanofi collaboration | By Jeff Craven
Currently, there are no FDA-approved therapies or vaccines for SARS-CoV-2, the virus that causes Covid-19. The National Institute of Allergy and Infectious Diseases (NIAID) within the National Institutes... |
| 09.04.2020 | Covid-19 Tracker updates vaccine candidates | By Jeff Craven
On March 11, the World Health Organization classified the Covid-19 outbreak as a pandemic. The disease has reached nearly every country, infecting hundreds of thousands of people and killing thousands.
Curr... |
| 14.11.2019 | In France, it’s illegal for consumers to order a DNA spit kit. Activists are fighting over lifting the ban | PARIS — From scanning her resume, you’d never guess Nathalie Jovanovic-Floricourt was an expert enabler of criminal activity. For years, she’d fretted over photo quality and page layout for publishing houses. Since 2007, she’s worked in com... |
| 15.03.2017 | David Beier Op-Ed: The World Is Completely Unprepared for a Global Pandemic | Article in Harvard Business Review
In 2003 a doctor with SARS unknowingly infected several guests while staying at a Hong Kong hotel, and overnight the virus reached across the globe. China is currently battling a bird flu that kills nearl... |
| 27.02.2017 | Safe and ethical ways to edit the human genome | More men are taking paid parental leave than ever before.
The National Academies of Science and Medicine (NASEM) released a report on February 14 exploring the implications of new technologies that can alter the genome of living organisms, ... |
| - | Услуга за услугу. Как русские учёные впряглись за Пастера в споре с антипрививочниками | В 2020 у нас появился новый повод гордиться Россией — вакцина от коронавируса, разработанная центром имени Н.Ф. Гамалеи.
Я расскажу о событиях 135-летней давности. О приключениях молодого доктора Гамалеи в Париже и о том, как в мире победил... |
